Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.60 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28043754 | 0.86 | HSP90AB1 (0.62) | HSP90AB1HSP90AA1ADCY10KDM4EAGPAT2 | |
| SCHEMBL13880351 | 0.81 | AGPAT2 (0.72) | AGPAT2 | |
| SCHEMBL4282884 | 0.80 | AGPAT2 (0.67) | HSP90AB1HSP90AA1JAK2KDM4EAGPAT2 | |
| SCHEMBL4281889 | 0.79 | HSP90AB1 (0.75) | HSP90AB1HSP90AA1KDM4EAGPAT2 | |
| SCHEMBL4286869 | 0.78 | AGPAT2 (0.70) | HSP90AB1HSP90AA1AGPAT2 | |
| SCHEMBL13880347 | 0.77 | AGPAT2 (0.74) | AGPAT2MEN1KMT2A | |
| SCHEMBL4291570 | 0.76 | HSP90AA1 (0.66) | HSP90AB1HSP90AA1KDM4EAGPAT2SMN1; SMN2 | |
| SCHEMBL4280537 | 0.76 | HSP90AA1 (0.71) | HSP90AB1HSP90AA1KDM4EAGPAT2 | |
| SCHEMBL3944846 | 0.76 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1KDM4EAGPAT2SMN1; SMN2 | |
| SCHEMBL30588697 | 0.75 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1ADCY10KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | HSP90AB1 4236/4885HSP90AA1 4126/4885ADCY10 1194/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | HSP90AB1 3829/4885HSP90AA1 4006/4885ADCY10 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.